secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001193125-23-184867
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular licenses R100 vector to Astellas for up to $300M per target in ophthalmic gene therapies
--------------------------------------------------------------------------------

- $20M upfront from Astellas; eligible for up to $42.5M in option/target substitution fees and $300M per target in milestones.
- Astellas gains exclusive worldwide license to 4DMT's R100 vector for up to three ophthalmic rare monogenic disease targets.
- Tiered royalties from mid-single digits to double-digit sub-teen percentage on net sales; subject to reductions.
- Astellas must use commercially reasonable efforts to develop and commercialize in US and at least two major EU markets.
- 4DMT agreed not to commercialize competing products for 7 years (through July 2030).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/0001193125-23-184867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/d466246d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-184867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer